Cagrilintide for Sale: How to Evaluate a Vendor Before You Buy
Cagrilintide is a long-acting amylin analogue under active clinical investigation. Before any research purchase, here is what the documentation and testing record should actually look like.
Cagrilintide is an investigational amylin analogue not approved by the FDA for any use; the only approved products containing cagrilintide-adjacent mechanisms are separate branded pharmaceuticals. When searching for cagrilintide for sale from a research-compound supplier, the minimum credible standard is a third-party certificate of analysis showing HPLC purity above 98%, mass spectrometry identity confirmation, and a clearly stated research-only policy. Vendors who omit COAs, make health claims, or obscure their testing lab should be avoided.
What Is Cagrilintide and Where Does It Stand Scientifically?
Cagrilintide is a long-acting acylated amylin analogue developed by Novo Nordisk. Amylin is a peptide co-secreted with insulin from pancreatic beta cells and plays a role in satiety signaling and gastric emptying. Cagrilintide was engineered to extend the half-life of native amylin, allowing once-weekly subcutaneous administration in clinical trials rather than the multiple-daily-injection schedule required by pramlintide, the only FDA-approved amylin analogue (marketed as Symlin).
The most prominent clinical program pairing cagrilintide with semaglutide, called CagriSema, has been studied in several Phase 2 and Phase 3 trials. A 2023 paper in The Lancet reported results from a 32-week Phase 2 trial in which participants with obesity received combination therapy; that study enrolled 92 participants and showed meaningful reductions in body weight compared to placebo. Phase 3 data under the REDEFINE program are ongoing as of 2024. Cagrilintide as a standalone compound was also evaluated in earlier Phase 2 work published in The Lancet Diabetes and Endocrinology in 2021, covering a 26-week trial of 706 participants.
None of this clinical activity translates to approval. Cagrilintide is not FDA-approved as a standalone drug or as part of any combination product. Researchers and institutions sourcing it for preclinical or early investigational work are operating in a research-chemical context, which carries its own documentation and quality requirements distinct from pharmaceutical supply chains.
What Does a Legitimate COA for Cagrilintide Actually Contain?
A certificate of analysis is the single most important document a vendor can provide, and for a peptide as structurally complex as cagrilintide, a superficial COA is nearly as useless as none at all. Cagrilintide has a molecular weight of approximately 3,900 daltons and includes a fatty acid acylation that distinguishes it from simpler linear peptides. That acylation is what drives its extended half-life, and it is also what makes identity confirmation non-trivial.
A credible COA should include high-performance liquid chromatography (HPLC) purity data with a result at or above 98%, a retention time trace, and mass spectrometry (MS) confirmation of the correct molecular weight. The MS result matters here more than it does for a simple peptide because the acyl chain must be present and intact for the compound to match the published structure. Some vendors provide only HPLC without MS; for cagrilintide specifically, that is an incomplete picture.
The COA should also name the testing laboratory, include a batch or lot number that matches the product label, and carry a test date. A COA dated more than 18 months before the purchase date raises questions about whether the current batch was actually tested or whether the vendor is recycling documentation from an earlier lot. Buyers should ask vendors directly whether the COA on file corresponds to the specific vial being shipped.
Red Flags That Should End the Evaluation Immediately
The most obvious red flag is a vendor making health or outcome claims about cagrilintide. Phrases like 'proven weight loss results,' 'treats obesity,' or any language implying the compound is equivalent to an approved drug are not just marketing overreach; they signal that the vendor either does not understand or does not care about the regulatory line between research chemicals and pharmaceuticals. A research-compound vendor's product pages should describe the compound's investigational status plainly.
Pricing that sits dramatically below market norms for a complex acylated peptide is another warning sign. Cagrilintide synthesis is more demanding than that of shorter, unmodified peptides. If a vendor is offering it at a price point that would be competitive for a simple 10-amino-acid peptide, the purity or identity of what is in the vial is legitimately in question. Cheap does not mean value here; it usually means corners were cut in synthesis or testing.
Vendors who cannot or will not name their third-party testing lab, who provide COAs as unverifiable image files with no lab letterhead, or who list no physical address or verifiable business registration should be removed from consideration. The research-chemical space has a real counterfeiting and mislabeling problem documented in published literature; a 2018 analysis in Drug Testing and Analysis found significant identity and purity discrepancies in peptides sold online. That finding is several years old, but the structural incentive for mislabeling has not changed.
Labeling, Storage Claims, and Shipping Practices
Cagrilintide is a peptide that degrades under improper storage conditions. A vendor's product label should state the recommended storage temperature, typically at or below minus 20 degrees Celsius for lyophilized powder, along with an expiration or best-by date tied to the specific lot. Generic labels that omit lot numbers or carry no expiration information suggest the vendor is not tracking inventory at the batch level, which makes COA matching impossible.
Shipping practices matter too. A vendor sending lyophilized peptides with no cold-pack option during warm months, or one that uses standard uninsulated envelopes for international shipments, is signaling indifference to product integrity. Some degradation during shipping is a known risk; a vendor who acknowledges it and takes steps to minimize it is more credible than one who ignores it entirely.
Return and replacement policies are a practical indicator of vendor confidence in their product. A vendor offering no recourse if a vial arrives damaged or if a customer's independent third-party test contradicts the COA is one that has structured the transaction to avoid accountability. Legitimate research suppliers generally offer replacement or credit for documented quality failures.
Research-Only Framing and What It Actually Means
Every credible research-compound vendor selling cagrilintide should state clearly that the product is intended for laboratory and research use only, is not for human consumption, and is not a pharmaceutical product. This framing is not just legal boilerplate; it reflects the actual regulatory status of the compound. Cagrilintide has no FDA approval, no IND exemption for general sale, and no status as a dietary supplement. It is an investigational peptide available through research-chemical channels.
Vendors who blur this framing, for example by including before-and-after imagery, testimonials about personal results, or language about how the compound 'works for' weight management, are misrepresenting the product's status. That misrepresentation is a compliance problem for the vendor and a signal to buyers that the operation is not being run with appropriate care.
The research-only designation also means buyers should be prepared to document the intended research use. Institutional buyers typically have procurement processes that handle this. Independent researchers should understand that purchasing a compound under a research-use framework carries its own responsibilities around handling, storage, and record-keeping that fall outside the scope of what any vendor can manage on a buyer's behalf.
Vetted vendors for research use
Our index screens vendor documentation against the checks in this review. We never accept payment for rank placement.
Frequently asked questions
Is cagrilintide the same as the drug used in the CagriSema trials?
Structurally yes, but the regulatory context is entirely different. The cagrilintide studied in Novo Nordisk's CagriSema Phase 2 and Phase 3 trials is a pharmaceutical-grade compound produced under strict GMP conditions and administered under clinical supervision. Research-chemical cagrilintide sold by third-party vendors is not produced under those conditions, has not been reviewed by the FDA, and is not approved for any use. The compound name refers to the same molecular structure, but pharmaceutical-grade and research-chemical are not interchangeable categories.
What purity level should a COA show for cagrilintide to be considered acceptable?
Most credible research-peptide vendors target HPLC purity at or above 98% for compounds like cagrilintide. Because cagrilintide includes a fatty acid acylation, mass spectrometry confirmation of the correct molecular weight is also necessary; HPLC alone cannot confirm that the acyl chain is present and intact. A COA showing 95% purity with no MS data is a weaker document than one showing 98% purity with both HPLC and MS results from a named third-party laboratory.
How can a buyer verify that a vendor's COA is real and not fabricated?
The most direct method is to contact the testing laboratory named on the COA and ask them to confirm the batch number and results. Legitimate analytical labs will confirm whether a report was issued by their facility. Buyers can also request the raw data files underlying the HPLC and MS results, not just the summary page. A vendor who refuses these requests or who cannot name the lab at all is providing documentation that cannot be independently verified, which is a significant red flag.
Sources
Sources are listed most recent first. Cited studies are peer-reviewed unless noted.
- Enebo et al., 2021, The Lancet Diabetes and Endocrinology, cagrilintide Phase 2 trial 26-week Phase 2 trial, 706 participants, cagrilintide monotherapy
- Frias et al., 2023, The Lancet, CagriSema Phase 2 trial 32-week Phase 2 combination trial, 92 participants
- van Egmond et al., 2018, Drug Testing and Analysis, peptide purity in online market Documents identity and purity discrepancies in online peptide sales
Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds not approved by the FDA or any equivalent authority for human use outside prescribed contexts. Always consult a licensed clinician before any health decision.
